Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Sensyne Health

DB:DSH
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DSH
DB
£51M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Sensyne Health plc, a healthcare technology company, engages in the development and commercialization of clinically validated software in the United Kingdom. The last earnings update was 70 days ago. More info.


Add to Portfolio Compare Print
  • Sensyne Health has significant price volatility in the past 3 months.
DSH Share Price and Events
7 Day Returns
15.6%
DB:DSH
4.1%
DE Healthcare Services
7.3%
DE Market
1 Year Returns
-76.7%
DB:DSH
0.9%
DE Healthcare Services
-17.7%
DE Market
DSH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sensyne Health (DSH) 15.6% -8.9% -41.5% -76.7% - -
DE Healthcare Services 4.1% -8.3% -18.1% 0.9% 24.9% 85.3%
DE Market 7.3% -17.9% -25.8% -17.7% -25.6% -29%
1 Year Return vs Industry and Market
  • DSH underperformed the Healthcare Services industry which returned 0.9% over the past year.
  • DSH underperformed the Market in Germany which returned -17.7% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Sensyne Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Sensyne Health to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Sensyne Health.

DB:DSH Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.7%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:DSH
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 6.1%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 0.97
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.973 (1 + (1- 19%) (4.21%))
1.004
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.004 * 6.07%)
5.7%

Discounted Cash Flow Calculation for DB:DSH using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Sensyne Health is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:DSH DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (GBP, Millions) Source Present Value
Discounted (@ 5.7%)
2020 -18.83 Analyst x1 -17.82
2021 -17.55 Analyst x1 -15.71
2022 -2.48 Analyst x1 -2.10
2023 16.10 Analyst x1 12.89
2024 29.24 Analyst x1 22.16
2025 40.10 Est @ 37.13% 28.74
2026 50.47 Est @ 25.88% 34.23
2027 59.55 Est @ 18% 38.21
2028 66.99 Est @ 12.48% 40.66
2029 72.76 Est @ 8.62% 41.78
Present value of next 10 years cash flows £183.00
DB:DSH DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= £72.76 × (1 + -0.39%) ÷ (5.7% – -0.39%)
£1,189.42
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= £1,189.42 ÷ (1 + 5.7%)10
£683.04
DB:DSH Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= £183.00 + £683.04
£866.04
Equity Value per Share
(GBP)
= Total value / Shares Outstanding
= £866.04 / 128.57
£6.74
DB:DSH Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:DSH represents 1.17x of AIM:SENS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.17x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (GBP) x Listing Adjustment Factor
= £ 6.74 x 1.17
€7.88
Value per share (EUR) From above. €7.88
Current discount Discount to share price of €0.47
= -1 x (€0.47 - €7.88) / €7.88
94.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Sensyne Health is available for.
Intrinsic value
>50%
Share price is €0.47 vs Future cash flow value of €7.88
Current Discount Checks
For Sensyne Health to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Sensyne Health's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Sensyne Health's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sensyne Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sensyne Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:DSH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-10-31) in GBP £-0.14
AIM:SENS Share Price ** AIM (2020-03-30) in GBP £0.4
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 11.1x
Germany Market PE Ratio Median Figure of 400 Publicly-Listed Companies 16.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sensyne Health.

DB:DSH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:SENS Share Price ÷ EPS (both in GBP)

= 0.4 ÷ -0.14

-2.78x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sensyne Health is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • Sensyne Health is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Sensyne Health's expected growth come at a high price?
Raw Data
DB:DSH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.78x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
61.4%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 14 Publicly-Listed Healthcare Services Companies 2.29x
Germany Market PEG Ratio Median Figure of 254 Publicly-Listed Companies 1.2x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sensyne Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sensyne Health's assets?
Raw Data
DB:DSH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-10-31) in GBP £0.43
AIM:SENS Share Price * AIM (2020-03-30) in GBP £0.4
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.88x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.43x
DB:DSH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:SENS Share Price ÷ Book Value per Share (both in GBP)

= 0.4 ÷ 0.43

0.92x

* Primary Listing of Sensyne Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sensyne Health is good value based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess Sensyne Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Sensyne Health has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Sensyne Health expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
61.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sensyne Health expected to grow at an attractive rate?
  • Sensyne Health's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Sensyne Health's earnings growth is expected to exceed the Germany market average.
  • Sensyne Health's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:DSH Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:DSH Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 61.4%
DB:DSH Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 60.8%
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 28.6%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 8.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.3%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:DSH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:DSH Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-04-30 69 36 28 1
2023-04-30 48 17 13 1
2022-04-30 26 -1 -6 1
2021-04-30 8 -15 -22 1
2020-04-30 2 -16 -23 1
2020-03-31
DB:DSH Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-10-31 0 -15 -19
2019-07-31 0 -15 -19
2019-04-30 0 -15 -19
2019-01-31 0 -13 -16
2018-10-31 0 -12 -14
2018-07-31 0 -10 -11
2018-04-30 0 -8 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sensyne Health's earnings are expected to grow significantly at over 20% yearly.
  • Sensyne Health's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:DSH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Sensyne Health Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DSH Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-04-30 0.22 0.22 0.22 1.00
2023-04-30 0.10 0.10 0.10 1.00
2022-04-30 0.00 0.00 0.00 1.00
2021-04-30 0.00 0.00 0.00 1.00
2020-04-30 0.00 0.00 0.00 1.00
2020-03-31
DB:DSH Past Financials Data
Date (Data in GBP Millions) EPS *
2019-10-31 -0.14
2019-07-31 -0.15
2019-04-30 -0.16
2019-01-31 -0.15
2018-10-31 -0.14
2018-07-31 -0.11
2018-04-30 -0.08

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sensyne Health will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Sensyne Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sensyne Health has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Sensyne Health performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sensyne Health's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sensyne Health does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Sensyne Health's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sensyne Health's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Sensyne Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sensyne Health Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DSH Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-10-31 0.49 -18.52 7.78 10.31
2019-07-31 0.31 -18.74 7.56 9.30
2019-04-30 0.14 -18.96 7.35 8.28
2019-01-31 0.12 -16.49 7.09 6.40
2018-10-31 0.10 -14.02 6.83 4.52
2018-07-31 0.09 -10.55 5.86 3.39
2018-04-30 0.08 -7.07 4.88 2.26

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sensyne Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sensyne Health has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sensyne Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sensyne Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sensyne Health has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Sensyne Health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sensyne Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sensyne Health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sensyne Health's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sensyne Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Sensyne Health has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sensyne Health Company Filings, last reported 5 months ago.

DB:DSH Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-10-31 55.79 0.00 40.49
2019-07-31 55.79 0.00 40.49
2019-04-30 65.41 0.00 49.25
2019-01-31 65.41 0.00 49.25
2018-10-31 74.43 0.00 57.66
2018-07-31 74.43 0.00 57.66
2018-04-30 12.22 0.00 4.54
  • Sensyne Health has no debt.
  • Sensyne Health has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sensyne Health has sufficient cash runway for 2.4 years based on current free cash flow.
  • Unable to confirm if Sensyne Health has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Sensyne Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sensyne Health has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Sensyne Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sensyne Health dividends. Estimated to be 0.42% next year.
If you bought €2,000 of Sensyne Health shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sensyne Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sensyne Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:DSH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 1.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 1%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:DSH Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2024-04-30
2023-04-30
2022-04-30 0.01 2.00
2021-04-30 0.00 2.00
2020-04-30 0.00 2.00
2020-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sensyne Health has not reported any payouts.
  • Unable to verify if Sensyne Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sensyne Health's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sensyne Health has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Sensyne Health's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Sensyne Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sensyne Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sensyne Health has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Sensyne Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Drayson
COMPENSATION £1,280,000
AGE 58
CEO Bio

Lord Paul Drayson, PhD FIET FREng? co-founded Drayson Technologies Ltd. in 2014 and serves as its Chairman of the Board and Chief Executive Officer. He is a Member of the House of Lords. Lord Drayson serves as the Chief Executive Officer at Sensyne Health plc and has been its Director since June 20, 2018. He is Science Entrepreneur in Residence at Magdalen College, Oxford. He served as Chairman and Chief Executive Officer of Chiron Pharmaceuticals Limited (alternative name PowderJect Pharmaceuticals Plc). He was appointed to the House of Lords and a Member of the Science and Technology Committee of the House of Lords in 2004. He was then appointed Parliamentary under Secretary of State for Defense Procurement in 2005 and became Minister of State for Defense Equipment & Support in 2006 and Minister of State for Science & Innovation in 2008. In 1991, he founded Genisys Development Limited. In 1993, he co-founded PowderJect Pharmaceuticals Plc and led its business as Chairman and Chief Executive Officer until 2003. He co-founded Drayson Racing Technologies LLP in 2007. He also worked in the automotive and food industries in marketing and new process development. In his previous role prior to PowderJect, he served as Managing Director of Lambourn Food Company Limited since 1987, where he led a management buy-out, acquired a competitor and successfully sold the combined operation. He has led several technology companies in different industry sectors. He served as chairman of BioIndustry Association since 2001. He has been an Independent Non-Executive Director at Airbus SE since April 12, 2017. He serves as a Non-Executive Director and Board Member of the Royal Navy until November 2017. He was Scientific Advisor of Formula E Championship until January 2013. He was President of the Motorsports Industry Association until October 2015. He is Chairman of the Executive Committee at OUC (Oxford University Clinic) Centres of Excellence LLP until December 2017. He is a Member of Project “Oxfordshire Innovation Engine” and Her Majesty’s Privy Council. He is a Co-Founder and Trustee of Drayson Foundation. He is Trustee and External Member of the Council of the University of Oxford. He is Supernumerary Fellow at St. John’s College, Oxford. He holds PhD in robotics in 1985 and BSc in robotics from Aston University.

CEO Compensation
  • Insufficient data for Paul to compare compensation growth.
  • Paul's remuneration is higher than average for companies of similar size in Germany.
Management Team

Paul Drayson

TITLE
CEO & Director
COMPENSATION
£1M
AGE
58

Lionel Tarassenko

TITLE
Director of R&D
COMPENSATION
£98K

Michael Norris

TITLE
Interim Chief Financial Officer

Roberto Liddi

TITLE
Senior Vice President of Quality Regulatory & Information Governance
TENURE
0.2 yrs

Nick Scott-Ram

TITLE
Chief of Strategic Development

Rabia Khan

TITLE
Chief of Translational medicine

Darren Lynch

TITLE
Head of Design
Board of Directors Tenure

Average tenure and age of the Sensyne Health board of directors in years:

1.4
Average Tenure
58
Average Age
  • The average tenure for the Sensyne Health board of directors is less than 3 years, this suggests a new board.
Board of Directors

Bruce Keogh

TITLE
Interim Independent Non-Executive Chair of the Board
COMPENSATION
£24K
TENURE
0.3 yrs

Paul Drayson

TITLE
CEO & Director
COMPENSATION
£1M
AGE
58
TENURE
1.7 yrs

Lionel Tarassenko

TITLE
Director of R&D
COMPENSATION
£98K
TENURE
1.4 yrs

Mary Hardy

TITLE
Senior Independent Director
COMPENSATION
£28K
TENURE
0.3 yrs

Vishal Gulati

TITLE
Independent Non-Executive Director
COMPENSATION
£24K
AGE
48
TENURE
1.6 yrs

David Clifton

TITLE
Member of Scientific Advisory Board

Peter Watkinson

TITLE
Member of Scientific Advisory Board

Lucy Mackillop

TITLE
Member of Scientific Advisory Board

Lloyd Minor

TITLE
Member of Scientific Advisory Board

Mike Bewick

TITLE
Member of Scientific Advisory Board
AGE
62
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Sensyne Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sensyne Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Sensyne Health plc, a healthcare technology company, engages in the development and commercialization of clinically validated software in the United Kingdom. Its products include SEND, an early warning system for monitoring patient vital signs in hospital; GDm-Health, a prescribed digital therapeutic for the management of gestational diabetes at home; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; and Support-HF, a prescribed digital therapeutic for monitoring heart failure at home. The company has strategic research alliance with Bayer's LifeHub UK to develop new treatments using clinical artificial intelligence. Sensyne Health plc was incorporated in 2018 and is headquartered in Oxford, the United Kingdom.

Details
Name: Sensyne Health plc
DSH
Exchange: DB
Founded: 2018
£57,828,391
128,571,514
Website: http://www.sensynehealth.com
Address: Sensyne Health plc
Schrodinger Building,
Heatley Road,
Oxford,
Oxfordshire, OX4 4GE,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM SENS Ordinary Shares London Stock Exchange AIM Market GB GBP 17. Aug 2018
DB DSH Ordinary Shares Deutsche Boerse AG DE EUR 17. Aug 2018
Number of employees
Current staff
Staff numbers
80
Sensyne Health employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 00:38
End of day share price update: 2020/03/30 00:00
Last estimates confirmation: 2020/03/01
Last earnings filing: 2020/01/21
Last earnings reported: 2019/10/31
Last annual earnings reported: 2019/04/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.